Is Progression-Free Survival 2 Ready for Prime Time in US Food and Drug Administration Regulatory Decision Making?
M
Mallorie H. Fiero
(Office of Biostatistics, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD)
M
Mirat Shah
(Office of Oncologic Diseases, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD)
L
Laleh Amiri-Kordestani
Article Details
Journal
Journal of Clinical Oncology
Volume / Issue
Vol. 44, Issue 20
Published
July 10, 2026
Pages
1865-1868
ISSN
0732-183X
Publisher
Lippincott Williams & Wilkins
Journal Info
Journal of Clinical Oncology
Lippincott Williams & Wilkins
ISSN: 0732-183X Health Sciences
Authors (3)
M
Mallorie H. Fiero
Office of Biostatistics, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD
M
Mirat Shah
Office of Oncologic Diseases, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD
L
Laleh Amiri-Kordestani
Related Articles from this Journal
Prostate-Specific Membrane Antigen Positron Emission Tomography and Radiometabolic Therapies in Metastatic Castration-Resistant Prostate Cancer
Ismaela Anna Vascotto, Filippo Antonica et al.
Aug 2026
10.1200/jco-26-00658
Allogeneic CD70-Targeted Chimeric Antigen Receptor T-Cell Therapy for Advanced Renal Cell Carcinoma: Results From the Phase I TRAVERSE Trial
Samer A. Srour, Jad Chahoud et al.
Aug 2026
10.1200/jco-26-00388
Adjuvant Carboplatin for Early-Stage, Triple-Negative Breast Cancer: Taxane and Patient Selection
Risako Komata, Kenju Ando et al.
Aug 2026
10.1200/jco-26-00140
Erratum: All-Oral Combination of Revumenib, Decitabine, and Venetoclax for Relapsed or Refractory AML (SAVE)
Ghayas C. Issa, Branko Cuglievan et al.
Aug 2026
10.1200/jco-26-01743
Reply to: Prostate-Specific Membrane Antigen Positron Emission Tomography and Radiometabolic Therapies in Metastatic Castration-Resistant Prostate Cancer
Irbaz Bin Riaz, R. Bryan Rumble et al.
Aug 2026
10.1200/jco-26-01001